pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,072 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT801Endpoints604BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32fda recalls20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Alcohol is wreaking havoc on U.S. public health. American society looks the other way
    The Deadliest Drug, a new investigative series, shows that the alcohol epidemic is a generational failure of the medical and public health systems, of industry, and of government.
    STAT · 2mo ago↗ source
  • 6 takeaways from STAT’s investigation into the U.S. alcohol epidemic
    Alcohol is the culprit behind the United States' most enduring and overlooked drug crisis. Here are 6 takeaways from STAT's new investigative series, The Deadliest Drug.
    STAT · 2mo ago↗ source
  • Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
    American biotech leaders are destroying their own industry.
    STAT · 2mo ago↗ source
← prev
page 33 of 43
next →
20
fda press20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Patients jockey for exemptions from Medicaid’s new work requirements
    Advocates for people with HIV and sickle cell disease are among those pushing for exemptions from Medicaid’s new work requirements.
    STAT · 2mo ago↗ source
  • STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
    Bristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.
    STAT · 2mo ago↗ source
  • Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL
    Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.
    onclive · 2mo ago↗ source
  • Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma
    Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
    onclive · 2mo ago↗ source
  • Supreme Court temporarily extends women’s access to a widely used abortion pill
    The Supreme Court is temporarily extending access to a widely used abortion pill while it considers whether to allow restrictions on the drug to take effect.
    STAT · 2mo ago↗ source
  • STAT+: Colombia wins a key court ruling over a compulsory license issued for an HIV medicine
    A South American court upheld the steps taken by the Colombian government when it issued a compulsory license two years ago for an HIV medicine.
    STAT · 2mo ago↗ source
  • Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
    Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
    onclive · 2mo ago↗ source
  • STAT+: Trump pivots on kratom derivative 7-OH, floating approval for some forms
    Last year, the FDA had warned that natural opioids in kratom were being turned into harmful products. Now President Trump says approval should be considered.
    STAT · 2mo ago↗ source
  • STAT+: Medicare’s miss on Alzheimer’s drug spending
    Far fewer seniors than expected are taking costly Alzheimer's drugs.
    STAT · 2mo ago↗ source
  • No FDA permission, no problem: New flavored vape policy worries experts
    A new FDA policy will let some flavored vapes stay on the market without authorization.
    STAT · 2mo ago↗ source
  • MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
    Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.
    onclive · 2mo ago↗ source
  • INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
    First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.
    onclive · 2mo ago↗ source
  • Treatment Intensification Gains Momentum in mCSPC Management
    During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.
    onclive · 2mo ago↗ source
  • STAT+: Astellas treatment offers new hope to a devastated rare disease community
    Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations
    Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.
    onclive · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
    People on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipated
    STAT · 2mo ago↗ source
  • Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT
    R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
    onclive · 2mo ago↗ source
  • Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection
    In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.
    onclive · 2mo ago↗ source
  • Expanding ctDNA Applications to RCC and Germ Cell Tumors
    Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.
    onclive · 2mo ago↗ source
  • RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice
    Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.
    onclive · 2mo ago↗ source
  • ctDNA in Metastatic Urothelial Carcinoma
    Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.
    onclive · 2mo ago↗ source
  • Institutional Perspectives on Treatment Thresholds in PLGG
    Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.
    onclive · 2mo ago↗ source